Friday, May 24, 2019 2:27:31 PM
I am not a biochemist and rarely reads patents, but the Brilacidin patents are written broadly with thousands of possible variations included and protected in the patent.
I have no knowledge on how thoroughly the various compounds have been screened for study, but the volume of the possible combinations means to me that it would be impossible to thoroughly study each compound for all of its possible effects.
The reason to seek patent protection is to give the company the right to defend its invention and that includes close variations in chemical structure.
GLTA Farrell
I look forward to seeing responses from others with more experience
Abstract:
The present invention provides methods for treating and/or preventing mucositis with one or more compounds, or pharmaceutically acceptable salts thereof, disclosed herein, or compositions comprising the same.
FIELD OF THE INVENTION
The present invention is directed, in part, to methods of treating and/or preventing mucositis with one or more compounds, or pharmaceutically acceptable salts thereof, disclosed herein, or compositions comprising the same.
http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=1&f=G&l=50&d=PTXT&p=1&S1=%22innovation+pharmaceuticals%22&OS=%22innovation+pharmaceuticals%22&RS=%22innovation+pharmaceuticals%22
Unfortunately the patent pages are not labeled, but the next section describes what are called claims of the invention.
Under the next section called summary of invention you will see
548 variations {STR00001 to STR00548} which are described each with a variety of possible chemical substitutions to produce different variations of the base compounds.
I did not try to calculate all the possibilities but my guess is it must be tens of thousands.
Under the section, Description of Embodiments, it defines chemical nature of the possible subsitutions . The patent also includes various structural variations isomers, oligmers etc.
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM